2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 108

A New Susceptibility Locus for Systemic Lupus Erythematosus on Chromosome 12
Abstract Number: 109

Association of HLA-G and Leukocyte Immunoglobulin-like Receptor A3 Polymorphisms with the Susceptibility to Pulmonary Hyterpention in Systemic Sclerosis
Abstract Number: 110

Genome-Wide DNA Epigenetic Profiling of Monozygotic Twins[L1] Discordant for ACPA or ACPA-Positive Rheumatoid Arthritis Reveals Novel Associated Genes
Abstract Number: 111

The Mitochondrial DNA (mtDNA) Haplogroups Influence the Risk of Radiographic OA Progression. a Meta-Analysis
Abstract Number: 112

The Molecular Genetic Analysis of the Autoinflammatory Syndromes in Russian Patients with Manifestation of Systemic Juvenile Idiopathic Arthritis
Abstract Number: 113

Longitudinal, Incremental Direct Medical Costs of Giant Cell Arteritis for the First Five Years Following Diagnosis: A General Population-Based Cohort Study
Abstract Number: 114

Surfing the Net: Patient Empowerment or Patient Deceit? Fifteen-Year Trends on the World Wide Web Information for Patients with Rheumatoid Arthritis
Abstract Number: 115

Validation of a Large Rheumatoid Arthritis Cohort and Preventive Health Screening
Abstract Number: 116

The Effect of the Formal Approval of Colchicine on Utilization of Emergency Department and Rheumatology Outpatient Services By Patients with Gout
Abstract Number: 117

Same Day Rheumatology Access Clinic in an Academic Health Care Center
Abstract Number: 118

Identifying the Investment Needed to Generate a Durable Prednisone Dose Decrement
Abstract Number: 119

Triage in Chronic Rheumatic Diseases: Quantitative Physician Estimates for Inflammation (Reversible), Damage (Irreversible), and Distress in Patients with Rheumatoid Arthritis, Osteoarthritis, and Fibromyalgia Seen in Usual Care
Abstract Number: 120

Validity of the Inpatient Diagnosis of Systemic Lupus Erythematosus: Clarifying Hospital Readmission Rates
Abstract Number: 121

Serum Uric Acid Levels and Gout Flares in a US Managed Care Setting
Abstract Number: 122

General Practitioners’ Perceptions of Methotrexate and Anti-TNF Therapies: A Qualitative Study

« Previous Page
1
…
7
8
9
10
11
…
218
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].